Breaking Down Synaptogenix, Inc. (SNPX) Financial Health: Key Insights for Investors

Are you keeping a close watch on Synaptogenix, Inc. (SNPX) and wondering about its financial stability? With a recent net loss of $14.7 million for the year ended 2024, how does this impact its future prospects? Delve into a detailed analysis of Synaptogenix's financial health, exploring critical insights from its 2024 fiscal year, including its ability to manage expenses, its cash flow concerns with only $0.2 million in cash, and the implications of its significant research and development spending. Keep reading to discover key financial indicators and what they mean for investors.

Synaptogenix, Inc. (SNPX) Revenue Analysis

Understanding Synaptogenix, Inc.'s financial health requires a detailed look at its revenue streams. As a biotechnology company focused on developing therapies for neurodegenerative diseases, Synaptogenix's revenue generation is unique. A comprehensive analysis includes examining the sources of revenue, historical growth, and the contribution of different business segments.

Here's a breakdown of Synaptogenix, Inc.'s revenue streams:

• Primary Revenue Sources:
  • Research and Development Grants: A significant portion of Synaptogenix's revenue comes from grants, particularly from the National Institutes of Health (NIH). In 2023, research grants contributed $975,000 to the total revenue.
  • Potential Licensing Agreements: Synaptogenix anticipates future revenue through licensing agreements for its drug candidates.
  • Potential Future Pharmaceutical Product Sales: The company expects to generate revenue from the sales of its pharmaceutical products, pending successful clinical trials and regulatory approvals.

Synaptogenix is focused on developing Bryostatin-1 for potential treatment of Alzheimer's disease.

Assessing Synaptogenix, Inc.'s revenue trends involves analyzing year-over-year growth rates and the factors influencing these changes. Examining historical data provides insights into the company's ability to generate and sustain revenue.

Key observations regarding Synaptogenix, Inc.'s revenue growth:

• Year-over-Year Revenue Growth Rate: Synaptogenix's revenue was reported as $0.00 for the twelve months ending December 31, 2023.
• Historical Revenue: According to WallStreetZen, Synaptogenix's annual revenue for the years 2018 through 2023 was $0.00.
• 2024 Revenue: Based on data as of December 31, 2024, Synaptogenix's revenue was -RMB21,786,602, compared to -RMB21,324,080 as of December 31, 2023, indicating a -1.81% decrease.

A review of Synaptogenix, Inc.'s revenue streams reveals how different segments contribute to the company's overall financial performance. Given its focus on Bryostatin-1, understanding the potential market value and development stage is crucial.

Key points regarding business segment contributions:

• Bryostatin-1: This drug candidate is in Phase 2 clinical trials with a potential market value estimated between $250-500 million.
• R&D Expenses: Research and development expenses decreased to $1,598,722 from $1,974,924, primarily due to the conclusion of the Phase 2 clinical trial for Alzheimer's Disease and the discontinuation of the dose-ranging study.

Analyzing changes in Synaptogenix, Inc.'s revenue streams involves identifying significant shifts and the factors driving them. These changes can reflect strategic decisions, market conditions, or the progress of clinical trials.

Significant changes in revenue streams include:

• Dependence on Research Grants: Synaptogenix relies heavily on research grants, with $975,000 received in 2023.
• Strategic Opportunities: The company is exploring strategic opportunities, including drug development platforms and new technologies, to enhance investor value and potentially create new revenue sources.

Here is a table summarizing Synaptogenix's key financial data:

For additional insights into Synaptogenix, Inc.'s financial health, you can read more at Breaking Down Synaptogenix, Inc. (SNPX) Financial Health: Key Insights for Investors.

Synaptogenix, Inc. (SNPX) Profitability Metrics

Analyzing Synaptogenix, Inc.'s (SNPX) profitability involves examining several key financial metrics. These metrics provide insights into the company's ability to generate profit from its revenue and manage its operational costs. Here's a breakdown of the company's profitability:

Gross Profit: For the fiscal year that ended in December 2024, Synaptogenix's gross profit was $0.00. Gross profit is calculated as revenue minus the cost of goods sold. A positive gross profit is essential for covering labor, equipment, rental, marketing, and R&D costs.

Gross Profit Margin: The gross margin for the quarter that ended in December 2024 is N/A (Not Applicable). Gross margin is calculated as gross profit divided by revenue. For Synaptogenix, since both revenue and cost of goods sold were $0, the gross margin could not be calculated.

Operating Income: The operating income for December 2024 was -$8.31 million. Operating income is calculated as gross profit minus operating expenses. A negative operating income indicates that the company's core operations are not profitable before considering interest and taxes.

Net Income: The net income for December 2024 was -$6.04 million. Net income is the profit remaining after all expenses, including interest and taxes, have been deducted from revenue. A negative net income indicates a net loss for the period.

Net Profit Margin: As of September 30, 2024, Synaptogenix's net profit margin was 0%. Net profit margin is net income divided by revenue, expressed as a percentage. A 0% net profit margin means the company did not retain any revenue as income after deducting all expenses.

Additional Insights:

Here's a summary of Synaptogenix's financial data from the income statement:

The company's financial statements for the year ending December 31, 2024, show a net loss of $12,768,549, compared to a net loss of $6,038,504 in the previous year. This increase in net loss was primarily due to a significant decrease in other income and increased losses from strategic investments. Research and development expenses also decreased to $1,598,722 from $1,974,924, mainly because the Phase 2 clinical trial for Alzheimer's Disease concluded and the dose-ranging study was discontinued.

For more insights into Synaptogenix, Inc. (SNPX), explore this resource: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc. (SNPX) Debt vs. Equity Structure

Understanding Synaptogenix, Inc.'s (SNPX) financial health requires a close look at how the company manages its debt and equity. This balance is crucial for funding growth and maintaining stability. Let's examine the key components of SNPX's debt structure, its debt-to-equity ratio, and recent financing activities.

Synaptogenix, Inc. (SNPX) primarily relies on equity financing rather than debt. As of the fiscal year 2024, the company reported minimal debt. Reviewing their financial statements indicates that their approach favors equity to fund operations and research initiatives. More details can be found in their filings with the Securities and Exchange Commission ().

Here’s a breakdown of Synaptogenix, Inc.'s (SNPX) debt and equity situation:

• Overview of Debt Levels:

Synaptogenix, Inc. (SNPX) has a notably low level of debt. In the third quarter of fiscal year 2024, the company reported total liabilities of $1.4 million, which includes both current and non-current liabilities. Given the nature of these liabilities, the company's reliance on debt is minimal, with a significant portion of their financing coming from equity. This approach is common for biotechnology firms that are in the research and development phase, where investments are made primarily through equity offerings rather than debt.

• Debt-to-Equity Ratio:

As of the third quarter of fiscal year 2024, Synaptogenix, Inc. (SNPX) has a debt-to-equity ratio of approximately 0.05. This low ratio indicates that the company is primarily financed by equity rather than debt. The total stockholders' equity was reported at $27.7 million, underscoring the company's reliance on equity to fund its operations and growth. This financial structure is typical for companies in the biotechnology sector, especially those focused on research and development, where equity financing is more common due to the high-risk, high-reward nature of drug development.

• Recent Financing Activities:

Synaptogenix, Inc. (SNPX) has been actively involved in equity financing to support its operations and research initiatives. For instance, they have conducted warrant exercises and public offerings to raise capital. While specific details of credit ratings are not available, the company's financing strategy indicates a preference for equity over debt.

Here's a summary of their recent financing activities:

• October 2023: Synaptogenix, Inc. (SNPX) announced the closing of a public offering, raising gross proceeds of approximately $7.0 million before deducting underwriting discounts and offering expenses.
• February 2024: The company announced the pricing of a public offering of units for gross proceeds of $8.0 million.
• March 2024: Synaptogenix, Inc. (SNPX) filed a prospectus supplement with the SEC related to an offering of common stock and warrants.

• Balancing Debt and Equity:

Synaptogenix, Inc. (SNPX) strategically balances debt and equity to fund its operations. With minimal debt, the company primarily uses equity financing to support its research and development activities. This approach reduces financial risk and provides flexibility, which is crucial for a company in the biotechnology sector. The decision to favor equity over debt reflects a cautious financial strategy aimed at sustaining long-term growth.

For more insights into Synaptogenix, Inc.'s (SNPX) investors, check out: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc. (SNPX) Liquidity and Solvency

Assessing Synaptogenix, Inc.'s financial health requires a close look at its liquidity and solvency positions. These metrics provide insights into the company's ability to meet its short-term obligations and long-term financial stability. Here’s an overview based on the latest available data:

Liquidity Ratios:

Liquidity ratios are essential tools for evaluating a company's ability to meet its short-term obligations. Synaptogenix, Inc.'s key liquidity ratios include:

• Current Ratio: A current ratio of 17.47 indicates that Synaptogenix, Inc. has sufficient current assets to cover its short-term liabilities.
• Quick Ratio: The quick ratio, also at 17.41, suggests the company has ample liquid assets to meet its immediate obligations.

These ratios reflect the company's capacity to use its current assets to cover its current liabilities.

Working Capital Trends:

Working capital, the difference between a company's current assets and current liabilities, is a measure of its short-term financial health. Synaptogenix, Inc.'s working capital as of December 31, 2024, was approximately $16.7 million, a decrease from $26.26 million in the previous year.

Cash Flow Statements Overview:

An examination of cash flow statements reveals how Synaptogenix, Inc. generates and uses cash. Key components include:

• Operating Cash Flow: Cash flow from operations reflects the cash generated from the company's core business activities.
• Investing Cash Flow: This includes cash used for investments in assets, such as property, plant, and equipment.
• Financing Cash Flow: Financing cash flow involves activities related to debt, equity, and dividends.

Synaptogenix, Inc. reported a net loss of $12,768,549 for the year, compared to a $6,038,504 loss in the previous year. This increase was primarily due to a significant decrease in other income and increased losses from strategic investments.

Cash Position:

As of December 31, 2024, Synaptogenix, Inc. had approximately $15 million in cash and cash equivalents. The company is also exploring strategic alternatives to enhance value for investors, including potential drug development platforms and new technologies.

Additional Insights:

Here's a breakdown of Synaptogenix, Inc.'s financial position:

Market Cap: $3.03 million

Enterprise Value: -$14.71 million

Synaptogenix, Inc. effected a one-for-twenty-five reverse stock split on April 4, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

See also Mission Statement, Vision, & Core Values of Synaptogenix, Inc. (SNPX).

Synaptogenix, Inc. (SNPX) Valuation Analysis

Determining whether Synaptogenix, Inc. (SNPX) is overvalued or undervalued requires a multifaceted approach, incorporating various financial ratios, stock performance analysis, and analyst opinions. Key metrics to consider include price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios. Additionally, examining the stock price trends over the past year, dividend yield (if applicable), and analyst consensus provides a comprehensive view.

As of April 2025, up-to-date financial ratios for Synaptogenix, Inc. (SNPX) are essential for an accurate valuation assessment. These ratios help contextualize the company's market value relative to its earnings, book value, and operational cash flow.

• Price-to-Earnings (P/E) Ratio: This ratio indicates how much investors are willing to pay for each dollar of Synaptogenix, Inc. (SNPX)'s earnings. A higher P/E ratio might suggest overvaluation if it's significantly above industry averages, while a lower P/E could indicate undervaluation.
• Price-to-Book (P/B) Ratio: The P/B ratio compares the company's market capitalization to its book value, offering insights into whether the stock is trading at a premium or discount to its net asset value.
• Enterprise Value-to-EBITDA (EV/EBITDA): This ratio provides a valuation measure that is independent of capital structure and accounting choices. It's particularly useful for comparing Synaptogenix, Inc. (SNPX) with other companies, especially if they have different levels of debt.

Analyzing Synaptogenix, Inc. (SNPX)’s stock price trends over the last 12 months (or longer) provides a historical perspective on market sentiment and performance. Significant price appreciation could suggest growing investor confidence, while a declining stock price might raise concerns about the company's prospects.

Given that Synaptogenix, Inc. (SNPX) does not currently offer dividends, dividend yield and payout ratios are not applicable to its valuation analysis. However, for companies that do distribute dividends, these metrics are crucial for assessing the sustainability and attractiveness of dividend payments.

Analyst consensus on Synaptogenix, Inc. (SNPX)’s stock valuation—whether it's rated as a buy, hold, or sell—reflects the collective opinion of financial experts. These ratings are typically based on thorough analysis of the company's financial performance, growth potential, and industry outlook.

For example, if the majority of analysts recommend a 'buy' rating, it suggests that the stock is undervalued and has potential for future growth. Conversely, a 'sell' rating indicates that analysts believe the stock is overvalued or faces significant risks.

Understanding who is investing in Synaptogenix, Inc. (SNPX) can offer additional insights into the company's valuation and future prospects. For a deeper dive into investor profiles, consider reading: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

A comprehensive valuation analysis necessitates examining these factors in totality, ensuring that investment decisions are well-informed and aligned with individual risk tolerance and investment objectives.

Synaptogenix, Inc. (SNPX) Risk Factors

Synaptogenix, Inc. (SNPX) faces a variety of risks, both internal and external, that could significantly impact its financial health. These risks span industry competition, regulatory changes, market conditions, and specific operational and strategic challenges detailed in their filings.

Industry Competition: The biotechnology industry is intensely competitive. Synaptogenix, Inc. (SNPX) competes with numerous companies, including major pharmaceutical firms, specialized biotech companies, and academic institutions, all striving to develop and market treatments for cognitive diseases. Successful products or technological advancements by competitors could render Synaptogenix, Inc. (SNPX)’s products obsolete or non-competitive. Intense competition may lead to difficulties in recruiting and retaining qualified personnel, forming collaborations, and acquiring new technologies.

Regulatory Risks: Clinical trials and the regulatory approval process are lengthy, expensive, and uncertain. Synaptogenix, Inc. (SNPX)’s reliance on favorable outcomes from clinical trials and approvals from regulatory bodies like the FDA introduces significant risk. Changes in regulatory requirements or policies could also impact the development and approval of its drug candidates. Delays in approvals can postpone revenue generation and increase operational costs.

Financial Risks: As of the fiscal year 2024, Synaptogenix, Inc. (SNPX) faces substantial financial risks. The company has a history of net losses, and there is no assurance of future profitability. For instance, the need to secure additional funding to continue research and development activities is critical, but obtaining such funding might not always be possible or available on favorable terms. Any additional debt financing could impose further financial strain, while equity financing might dilute existing shareholders' stakes.

Operational and Strategic Risks: Operational risks include challenges in scaling up manufacturing, managing supply chains, and protecting intellectual property. Strategic risks involve the successful execution of business plans, including partnering and commercialization strategies. Failure to effectively manage these operational and strategic aspects could adversely affect the company's financial performance.

Synaptogenix, Inc. (SNPX) outlines several risk mitigation strategies in its filings. These include:

• Diversifying its product pipeline to reduce dependence on a single drug candidate.
• Strengthening its intellectual property portfolio through patents and other protections.
• Building strategic alliances and partnerships to share development costs and risks.
• Implementing rigorous quality control and risk management processes across its operations.

Here is a summary of key financial data that reflects some of the risks mentioned:

Understanding these risks is crucial for investors. For a deeper dive into who is investing in Synaptogenix, Inc. (SNPX) and why, consider reading: Exploring Synaptogenix, Inc. (SNPX) Investor Profile: Who’s Buying and Why?

Synaptogenix, Inc. (SNPX) Growth Opportunities

Synaptogenix, Inc. (SNPX) faces a landscape ripe with potential for future growth, driven by a combination of factors ranging from innovative product development to strategic market positioning. A thorough analysis reveals several key drivers that could significantly impact the company's trajectory.

Key growth drivers for Synaptogenix, Inc. (SNPX) include:

• Product Innovations: The primary driver for Synaptogenix, Inc. (SNPX)'s growth is its focus on developing innovative therapies for neurodegenerative diseases.
• Market Expansion: As clinical trials progress and potential FDA approvals loom, Synaptogenix, Inc. (SNPX) can explore expanding its market reach.
• Strategic Initiatives and Partnerships: Strategic collaborations and partnerships could provide Synaptogenix, Inc. (SNPX) with access to additional resources, funding, and expertise.
• Competitive Advantages: Synaptogenix, Inc. (SNPX)'s competitive edge lies in its unique approach to treating Alzheimer's disease and other neurodegenerative conditions.

Future revenue growth projections and earnings estimates for Synaptogenix, Inc. (SNPX) are contingent upon successful clinical trial outcomes and regulatory approvals. The company's financial performance is closely tied to the advancement of its lead drug candidate, Bryostatin-1, through the clinical development pipeline.

Strategic initiatives that may drive future growth include:

• Advancing Bryostatin-1 through clinical trials for Alzheimer's disease and other neurodegenerative disorders.
• Pursuing strategic partnerships with pharmaceutical companies or research institutions.
• Exploring opportunities to expand the application of Bryostatin-1 to other therapeutic areas.

Synaptogenix, Inc. (SNPX) possesses several competitive advantages that could position the company for growth:

• Novel Therapeutic Approach: Bryostatin-1 represents a novel approach to treating Alzheimer's disease by targeting synaptogenesis and neuroinflammation.
• Clinical Data: Positive clinical data from previous trials of Bryostatin-1 provide a foundation for further development and potential regulatory approval.
• Intellectual Property: Synaptogenix, Inc. (SNPX) holds intellectual property rights to Bryostatin-1, which could provide a competitive advantage in the market.

For more information about the company's mission, vision, and core values, visit Mission Statement, Vision, & Core Values of Synaptogenix, Inc. (SNPX).